AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8729628 — intervention group
Group type: COMPARATOR
Intervention: Uninfected classmates (N = 48)
Number of subjects: 97
Study 1824708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing women who ovulated within 6 months postpartum
Number of subjects: 58
Study 1824708 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with longer lactational amenorrhea
Number of subjects: 58
Study 1824708 — intervention group
Group type: COMPARATOR
Intervention: Women with shorter lactational amenorrhea
Number of subjects: 58
Study 7070255 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to simulated altitude (barometric pressures of 681, 656, 632, and 574 mmHg simulating altitudes of 914, 1219, 1524, and 2286 m)
Number of subjects: 12
Study 7070255 — intervention group
Group type: COMPARATOR
Intervention: Control altitude (362 m, barometric pressure = 730 mmHg)
Number of subjects: 12
Study 30969962 — intervention group
Group type: EXPERIMENTAL
Intervention: Only children with overweight/obesity
Number of subjects: 1348
Study 30969962 — intervention group
Group type: EXPERIMENTAL
Intervention: Only children
Number of subjects: 1348
Study 30969962 — intervention group
Group type: COMPARATOR
Intervention: Peers with siblings
Number of subjects: 1348
Study 29236722 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 1206
Study 29236722 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1206
Study 25880234 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based diabetes self-management education (DSME) intervention targeting empowerment
Number of subjects: 516
Study 25880234 — intervention group
Group type: COMPARATOR
Intervention: Control group (six lectures on unrelated geriatrics topics)
Number of subjects: 516
Study 22999262 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress task (Trier Social Stress Test)
Number of subjects: 46
Study 22999262 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 46
Study 22900437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instruments
Number of subjects: 80
Study 22900437 — intervention group
Group type: EXPERIMENTAL
Intervention: Airotor
Number of subjects: 80
Study 22900437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 80
Study 22900437 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 80
Study 22900437 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 19563680 — intervention group
Group type: COMPARATOR
Intervention: no electronic games
Number of subjects: 72
Study 19563680 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional electronic games
Number of subjects: 72
Study 19563680 — intervention group
Group type: EXPERIMENTAL
Intervention: active electronic games
Number of subjects: 72
Study 19563680 — intervention group
Group type: EXPERIMENTAL
Intervention: all conditions
Number of subjects: 72
Study 17044088 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular therapy (NMT)
Number of subjects: 36
Study 17044088 — intervention group
Group type: COMPARATOR
Intervention: Music relaxation (MR, active control)
Number of subjects: 36
Study 15199082 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg qd) for 4 days followed by aspirin (100 mg qd) for 7 days
Number of subjects: 16
Study 15199082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg qd) for 7 days after meloxicam
Number of subjects: 16
Study 15199082 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg) for 2 days
Number of subjects: 16
Study 11778778 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated form of the Portland Digit Recognition Test (PDRT)
Number of subjects: 80
Study 11778778 — intervention group
Group type: COMPARATOR
Intervention: Full scale Portland Digit Recognition Test (PDRT)
Number of subjects: 80
Study 11778778 — intervention group
Group type: COMPARATOR
Intervention: Warned Simulators (control group)
Number of subjects: 80
Study 9393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal incision (1,705 implants)
Number of subjects: 522
Study 9393424 — intervention group
Group type: COMPARATOR
Intervention: Remote incision (593 implants)
Number of subjects: 522
Study 7943676 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) 25.0 mg/kg
Number of subjects: 41
Study 7943676 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) 12.5 mg/kg
Number of subjects: 41
Study 7943676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3370038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after 24 hours of head-down bed rest
Number of subjects: 10
Study 3370038 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after being seated for 1 hour
Number of subjects: 10
Study 31648705 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab + Standard of Care (SOC)
Number of subjects: 1255
Study 31648705 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1255
Study 28511584 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused intervention program
Number of subjects: 60
Study 28511584 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 60
Study 25590831 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh soaked in vancomycin solution (Group 2)
Number of subjects: 52
Study 25590831 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 52
Study 23147209 — intervention group
Group type: EXPERIMENTAL
Intervention: rimonabant 20 mg/day
Number of subjects: 289
Study 23147209 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 289
Study 21519360 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 20 mg daily
Number of subjects: 156
Study 21519360 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 40 mg daily
Number of subjects: 156
Study 21519360 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 60 mg daily
Number of subjects: 156
Study 21519360 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP) 30 mg twice daily
Number of subjects: 156
Study 21519360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 19024539 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscope
Number of subjects: 112
Study 19024539 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscope
Number of subjects: 112
Study 16480474 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g intravenously, 5 h apart (n = 40)
Number of subjects: 120
Study 16480474 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscularly (n = 40)
Number of subjects: 120
Study 16480474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 120
Study 12937335 — intervention group
Group type: EXPERIMENTAL
Intervention: skills training condition
Number of subjects: 118
Study 12937335 — intervention group
Group type: COMPARATOR
Intervention: minimal support control condition
Number of subjects: 118
Study 10729298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal application of oxygen at a constant flow of 2 l/min
Number of subjects: 40
Study 10729298 — intervention group
Group type: COMPARATOR
Intervention: Ambient air at a constant flow of 2 l/min
Number of subjects: 40
Study 9575599 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 120
Study 9575599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8222122 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 20 mg/d)
Number of subjects: 108
Study 8222122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 3532605 — intervention group
Group type: EXPERIMENTAL
Intervention: New Rift Valley fever vaccine (formalin‐inactivated, prepared in diploid fetal rhesus lung cells)
Number of subjects: 0
Study 3532605 — intervention group
Group type: EXPERIMENTAL
Intervention: Various vaccine lots
Number of subjects: 0
Study 3532605 — intervention group
Group type: COMPARATOR
Intervention: Conventional pre‐filtration or pre‐inactivation virus infectivity assays
Number of subjects: 0
Study 3532605 — intervention group
Group type: COMPARATOR
Intervention: Animal potency tests
Number of subjects: 0
Study 29426300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol 0.5 mcg daily for 6 weeks
Number of subjects: 40
Study 29426300 — intervention group
Group type: COMPARATOR
Intervention: Identically-matched placebo for 6 weeks
Number of subjects: 40
Study 28861980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gushen Antai pills combined with progesterone
Number of subjects: 112
Study 28861980 — intervention group
Group type: COMPARATOR
Intervention: Progesterone (control group)
Number of subjects: 112
Study 24683592 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracore + polydopamine
Number of subjects: 40
Study 24683592 — intervention group
Group type: COMPARATOR
Intervention: Paracore + control
Number of subjects: 40
Study 24683592 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem + polydopamine
Number of subjects: 40
Study 24683592 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem + control
Number of subjects: 40
Study 23053639 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL (radioguided occult lesion localisation)
Number of subjects: 314
Study 23053639 — intervention group
Group type: COMPARATOR
Intervention: WGL (wire-guided localisation)
Number of subjects: 314
Study 20141567 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate, high saturated fat diet (LC)
Number of subjects: 49
Study 20141567 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric high carbohydrate, low fat diet (LF)
Number of subjects: 49
Study 18677973 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate plus reproterol (DSCG/REP) inhalation 20 min before exercise challenge
Number of subjects: 24
Study 18677973 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (MON) oral treatment for 3 days
Number of subjects: 24
Study 18677973 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate plus reproterol (DSCG/REP) adjusted
Number of subjects: 24
Study 18677973 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate plus reproterol (DSCG/REP) unadjusted
Number of subjects: 24
Study 15918822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% (Group E)
Number of subjects: 19
Study 15918822 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 19
Study 12911187 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 0
Study 12911187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 12911187 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 10561733 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative administration of a serine protease inhibitor
Number of subjects: 20
Study 10561733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no serine protease inhibitor)
Number of subjects: 20
Study 8572007 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (ampicillin-sulbactam and amoxicillin-clavulanic acid)
Number of subjects: 78
Study 8572007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8297564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 9
Study 8297564 — intervention group
Group type: COMPARATOR
Intervention: Hemofiltration (HF)
Number of subjects: 9
Study 8297564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) and Hemofiltration (HF)
Number of subjects: 9
Study 31285376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy under assumed ideal conditions
Number of subjects: 607
Study 31285376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy under current local resources (night time scenarios)
Number of subjects: 607
Study 31285376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy under current local resources (daytime scenarios)
Number of subjects: 607
Study 31285376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy under assumed ideal conditions (daytime scenarios)
Number of subjects: 607
Study 31285376 — intervention group
Group type: COMPARATOR
Intervention: Night time presentation
Number of subjects: 607
Study 30513824 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-gluten diet
Number of subjects: 0
Study 30513824 — intervention group
Group type: COMPARATOR
Intervention: Normal-gluten diet
Number of subjects: 0
Study 27388357 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (active vitamin D analogue)
Number of subjects: 0
Study 27388357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25608583 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir 600 mg/100 mg
Number of subjects: 16
Study 25608583 — intervention group
Group type: COMPARATOR
Intervention: darunavir 800 mg/100 mg
Number of subjects: 16
Study 24364448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometers, motivational brochures, and Internet programme for 4 weeks
Number of subjects: 495
Study 24364448 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 495
Study 21708057 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg of DHEAS
Number of subjects: 0
Study 21708057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17702595 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 259
Study 17702595 — intervention group
Group type: COMPARATOR
Intervention: Control group (elderly patients)
Number of subjects: 259
Study 16776915 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted-dose, INR 2.0 - 3.0)
Number of subjects: 704
Study 16776915 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (150 mg - 160 mg once daily)
Number of subjects: 704
Study 12584227 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 130
Study 12584227 — intervention group
Group type: EXPERIMENTAL
Intervention: interferon (IFN)
Number of subjects: 130
Study 12584227 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-lamivudine combination therapy
Number of subjects: 130
Study 9880387 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge to community therapy
Number of subjects: 274
Study 9880387 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm of the trial
Number of subjects: 274
Study 9880387 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy, meals on wheels, home help visits
Number of subjects: 274
Study 7662102 — intervention group
Group type: EXPERIMENTAL
Intervention: Acardust
Number of subjects: 32
Study 7662102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2678880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives
Number of subjects: 20
Study 2678880 — intervention group
Group type: COMPARATOR
Intervention: No oral contraceptives
Number of subjects: 20
Study 794978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (tricyclic compound, non-amphetamine) for 8 weeks
Number of subjects: 20
Study 794978 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 20
Study 30303612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/Acetaminophen combination
Number of subjects: 1485
Study 30303612 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 1485
Study 30303612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1485
Study 27791258 — intervention group
Group type: EXPERIMENTAL
Intervention: Femorally inserted venous catheters (FIVCs) with exit site at mid-thigh (NOV)
Number of subjects: 114
Study 27791258 — intervention group
Group type: COMPARATOR
Intervention: Femorally inserted venous catheters (FIVCs) with exit site at groin (CON)
Number of subjects: 114
Study 26228621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants applied to occlusal surfaces of primary molars
Number of subjects: 147
Study 26228621 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish applications
Number of subjects: 147
Study 23706546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 100 mg bupivacaine in 100 mL normal saline solution
Number of subjects: 160
Study 23706546 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 160
Study 23706546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 100 mg bupivacaine
Number of subjects: 160
Study 21210001 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem
Number of subjects: 20
Study 21210001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement
Number of subjects: 20
Study 19246041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined self-management and relaxation-breathing training
Number of subjects: 48
Study 19246041 — intervention group
Group type: COMPARATOR
Intervention: Self-management-only training (Control)
Number of subjects: 48
Study 16388958 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft and ventricular restoration (Group 1b, 39 patients)
Number of subjects: 137
Study 16388958 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (Group 1a, 35 patients)
Number of subjects: 137
Study 16388958 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft and ventricular reconstruction (Group 2, 69 patients)
Number of subjects: 137
Study 16388958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral regurgitation grades 1 to 2+
Number of subjects: 137
Study 16388958 — intervention group
Group type: EXPERIMENTAL
Intervention: End-systolic volume
Number of subjects: 137
Study 16388958 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure class (NYHA)
Number of subjects: 137
Study 15518637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spinal cord injury (SCI) subjects
Number of subjects: 31
Study 15518637 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 31
Study 11021956 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 426
Study 11021956 — intervention group
Group type: COMPARATOR
Intervention: valsartan 80 mg
Number of subjects: 426
Study 9256871 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 20% of maximal inspiratory pressure (MIP) for 5 to 15 minutes, three times a day, for 8 weeks
Number of subjects: 14
Study 7945125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 179
Study 7945125 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 179
Study 3582722 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg amoxycillin twice daily
Number of subjects: 50
Study 3582722 — intervention group
Group type: COMPARATOR
Intervention: 750 mg amoxycillin three times daily
Number of subjects: 50
Study 30144658 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of aggressive behaviors identified using the Korean interRAI Long‐Term Care Facility Assessment Tool.
Number of subjects: 1447
Study 30144658 — intervention group
Group type: EXPERIMENTAL
Intervention: Social engagement as a contributing factor.
Number of subjects: 1447
Study 27802417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (0.3 mg kg ‐1) after placebo
Number of subjects: 15
Study 27802417 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitrite (0.3 mg kg ‐1) after esomeprazole (3×40 mg)
Number of subjects: 15
Study 27802417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (1, 10, and 30 nmol kg ‐1 min ‐1) intravenously
Number of subjects: 15
Study 26017285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile double-compression-coated tablets
Number of subjects: 0
Study 26017285 — intervention group
Group type: EXPERIMENTAL
Intervention: Core mini-tablets
Number of subjects: 0
Study 23064732 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pilates exercises (12 sessions over 6 weeks)
Number of subjects: 86
Study 23064732 — intervention group
Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 86
Study 21186984 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy + kefir (n=46)
Number of subjects: 82
Study 21186984 — intervention group
Group type: COMPARATOR
Intervention: triple therapy + placebo (n=36)
Number of subjects: 82
Study 21186984 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy + kefir
Number of subjects: 82
Study 21186984 — intervention group
Group type: COMPARATOR
Intervention: triple therapy + placebo
Number of subjects: 82
Study 18679637 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical preparation containing urea, vitamins, and ceramides for 2 weeks
Number of subjects: 10
Study 18679637 — intervention group
Group type: COMPARATOR
Intervention: Topical urea-only preparation
Number of subjects: 10
Study 16792302 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-coded steady-state visual evoked potentials (VEP) based brain-computer interface
Number of subjects: 0
Study 14572570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 105
Study 14572570 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Therapy
Number of subjects: 105
Study 14572570 — intervention group
Group type: COMPARATOR
Intervention: Routine Clinical Care
Number of subjects: 105
Study 14572570 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (CBT, Relaxation, Routine Care)
Number of subjects: 105
Study 11198055 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 0
Study 11198055 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 0
Study 9011451 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with muddy pigment stones (intervention group)
Number of subjects: 208
Study 9011451 — intervention group
Group type: COMPARATOR
Intervention: Patients without gallstones (control group)
Number of subjects: 208